| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ... Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013 | 836 | 2013 |
| The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 AA Wylie, J Schoepfer, W Jahnke, SW Cowan-Jacob, A Loo, P Furet, ... Nature 543 (7647), 733-737, 2017 | 490 | 2017 |
| Moving treatment-free remission into mainstream clinical practice in CML TP Hughes, DM Ross Blood, The Journal of the American Society of Hematology 128 (1), 17-23, 2016 | 358 | 2016 |
| Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ... New England Journal of Medicine 381 (24), 2315-2326, 2019 | 343 | 2019 |
| Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, PA Bartley, ... Leukemia 24 (10), 1719-1724, 2010 | 337 | 2010 |
| Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study A Hochhaus, T Masszi, FJ Giles, JP Radich, DM Ross, ... Leukemia 31 (7), 1525-1531, 2017 | 302 | 2017 |
| Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline S Branford, DT Yeung, WT Parker, ND Roberts, L Purins, JA Braley, ... Blood, The Journal of the American Society of Hematology 124 (4), 511-518, 2014 | 221 | 2014 |
| Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML S Branford, DT Yeung, DM Ross, JA Prime, CR Field, HK Altamura, ... Blood, The Journal of the American Society of Hematology 121 (19), 3818-3824, 2013 | 219 | 2013 |
| Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease S Branford, P Wang, DT Yeung, D Thomson, A Purins, C Wadham, ... Blood, The Journal of the American Society of Hematology 132 (9), 948-961, 2018 | 180 | 2018 |
| Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study DM Ross, T Masszi, MT Gómez Casares, A Hellmann, J Stentoft, ... Journal of cancer research and clinical oncology 144, 945-954, 2018 | 148 | 2018 |
| Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib CY Cheah, K Burbury, JF Apperley, F Huguet, V Pitini, M Gardembas, ... Blood, The Journal of the American Society of Hematology 123 (23), 3574-3577, 2014 | 143 | 2014 |
| Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL DM Ross, S Branford, S Moore, TP Hughes Leukemia 20 (4), 664-670, 2006 | 117 | 2006 |
| TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets DT Yeung, MP Osborn, DL White, S Branford, J Braley, A Herschtal, ... Blood, The Journal of the American Society of Hematology 125 (6), 915-923, 2015 | 105 | 2015 |
| Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia EJ Duncavage, A Bagg, RP Hasserjian, CD DiNardo, LA Godley, ... Blood, The Journal of the American Society of Hematology 140 (21), 2228-2247, 2022 | 79 | 2022 |
| Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells DM Ross, IS Pagani, N Shanmuganathan, CH Kok, JF Seymour, AK Mills, ... Leukemia 32 (12), 2572-2579, 2018 | 75 | 2018 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ... The Lancet 401 (10373), 269-280, 2023 | 74 | 2023 |
| Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR‐ABL DNA PA Bartley, DM Ross, S Latham, MH Martin‐Harris, B Budgen, V Wilczek, ... International journal of laboratory hematology 32 (6p1), e222-e228, 2010 | 69 | 2010 |
| Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome D Singhal, MM Kutyna, R Chhetri, LYA Wee, S Hague, L Nath, SV Nath, ... Haematologica 102 (12), 2021, 2017 | 68 | 2017 |
| How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia DM Ross, TP Hughes British journal of haematology 166 (1), 3-11, 2014 | 64 | 2014 |
| Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells YD Irani, A Hughes, J Clarson, CH Kok, N Shanmuganathan, DL White, ... British Journal of Haematology 191 (3), 433-441, 2020 | 61 | 2020 |
